Skip to main content
SpringerLink
Log in

Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Left ventricular (LV) remodeling describes dynamic changes in ventricular size and shape that result from hemodynamic and metabolic insults to the failing heart. The remodeling hypothesis in heart failure asserts that LV remodeling is the central pathophysiologic lesion whereby alterations in cardiac structure are followed by impairment in function, with a wide range of genetic-environment interactions that determine the ultimate phenotype. Several therapeutic targets of LV remodeling have already been exploited (such as neurohormonal and cytokine activation). On the other hand, great efforts are still being made to understand the complex array of genetic and metabolic derangements. Nevertheless, we have realized that there is no single phenotypic change, protein expression, or signal-transduction pathway that is dominant in the process of cardiac remodeling. This implies that better characterization of this heterogeneous heart failure phenotype is desperately needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Francis GS, Tang WH: Pathophysiology of congestive heart failure. Rev Cardiovasc Med 2003, 4:S14-S20.

    PubMed  Google Scholar 

  2. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling — concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569–582. This is an important consensus statement regarding the modern concepts and clinical implications of cardiac remodeling in understanding the pathophysiology of heart failure.

    Article  PubMed  CAS  Google Scholar 

  3. Metra M, Nodari S, Parrinello G, et al.: Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003, 145:292–299.

    Article  PubMed  Google Scholar 

  4. Kawai K, Takaoka H, Hata K, et al.: Prevalence, predictors and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 84:671–676.

    Article  PubMed  CAS  Google Scholar 

  5. Tang WHW, Larson MS, Prikazsky L, et al.: Reversal remodeling following long-term carvedilol therapy is associated with improvement in survival: the Stanford carvedilol echocardiographic registry [abstract]. J Am Coll Cardiol 2002, 39:141A.

    Article  Google Scholar 

  6. Konstam MA, Udelson JE, Anand IS, et al.: Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003, 9:350–353. This paper summarizes the remodeling hypothesis and suggests the concept of using ventricular remodeling as surrogate endpoints.

    Article  PubMed  Google Scholar 

  7. Morgan HE, Baker KM: Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 1991, 83:13–25.

    PubMed  CAS  Google Scholar 

  8. Katz AM: Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drug Ther 2002, 16:245–249. A concise and up to date review of the pathophysiology of cardiac hypertrophy and remodeling.

    Article  CAS  Google Scholar 

  9. Francis GS, McDonald KM, Cohn JN: Neurohormoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 1993, 87:IV90-IV96.

    PubMed  CAS  Google Scholar 

  10. Dalby MCD, Burke M, Radley-Smith R, et al.: Pheochromocytoma presenting after cardiac transplantation for dilated cardiomyopathy. J Heart Lung Transplant 2001, 20:773–775.

    Article  PubMed  CAS  Google Scholar 

  11. Greenberg B, Quinones MA, Koilpillai C, et al.: Effects of longterm enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573–2581.

    PubMed  CAS  Google Scholar 

  12. Konstam MA, Kronenberg MW, Rousseau MF, et al.: Effects of angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277–2283.

    PubMed  CAS  Google Scholar 

  13. Cuspidi C, Muiesan ML, Valagussa L, et al.: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002, 20:2203–2300.

    Google Scholar 

  14. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056–1064.

    PubMed  CAS  Google Scholar 

  15. Wachtell K, Dahlof B, Rokkedal J, et al.: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002, 144:1057–1064.

    Article  PubMed  CAS  Google Scholar 

  16. McKelvie RS, Rouleau JL, White M, et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003, 24:1727–1734.

    Article  PubMed  CAS  Google Scholar 

  17. Hayashi M, Tsutamoto T, Wada A, et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559–2565.

    Article  PubMed  CAS  Google Scholar 

  18. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  19. Lowes BD, Gill EA, Abraham WT, et al.: Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83:1201–1205.

    Article  PubMed  CAS  Google Scholar 

  20. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970–975.

    Article  PubMed  CAS  Google Scholar 

  21. Schleman KA, Lindenfeld JA, Lowes BD, et al.: Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 2001, 7:4–12.

    Article  PubMed  CAS  Google Scholar 

  22. Tang WH, Francis GS: Novel pharmacological treatments for heart failure. Expert Opin Investig Drugs 2003, 12:1791–1801.

    Article  PubMed  CAS  Google Scholar 

  23. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988–998. An up to date review of the role of inflammation in the pathophysiology of heart failure.

    Article  PubMed  CAS  Google Scholar 

  24. Mann DL, Taegtmeyer H: Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart. Recovering the missing link in left ventricular remodeling. Circulation 2001, 104:1089–1091.

    PubMed  CAS  Google Scholar 

  25. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341–348.

    Article  PubMed  CAS  Google Scholar 

  26. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circ Res 1991, 83:1849–1865.

    CAS  Google Scholar 

  27. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  28. Zannad F, Dousset B: Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227–1232.

    PubMed  CAS  Google Scholar 

  29. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes. Part I: general concepts. Circulation 2002, 105:1727–1733.

    Article  PubMed  CAS  Google Scholar 

  30. Young ME, McNulty P, Taegtmeyer H: Adaptation and maladaptation of the heart in diabetes. Part II: potential mechanisms. Circulation 2002, 105:1861–1870.

    Article  PubMed  CAS  Google Scholar 

  31. Dyntar D, Eppenberger-Eberhardt M, Maedler K, et al.: Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001, 50:2105–2113.

    Article  PubMed  CAS  Google Scholar 

  32. Del Monte F, Johnson CM, Stepanek AC, et al.: Defects in calcium control. J Card Fail 2002, 8:S421-S431.

    Article  PubMed  Google Scholar 

  33. St John Sutton MG, Plappert T, Abraham WT, et al.: Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107:1985–1990.

    Article  PubMed  Google Scholar 

  34. Le Corvoisier P, Park HY, Rockman HA: Modifier genes and heart failure. Minerva Cardioangiol 2003, 51:107–120.

    PubMed  CAS  Google Scholar 

  35. Liao Y, Cooper RS, McGee DL, et al.: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995, 273:1592–1597.

    Article  PubMed  CAS  Google Scholar 

  36. Houghton JL, Prisant LM, Carr AA, et al.: Racial differences in myocardial ischemia and coronary flow reserve in hypertension. J Am Coll Cardiol 1994, 23:1123–1129.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, 44195, Cleveland, OH, USA

    W.H. Wilson Tang MD

Authors
  1. W.H. Wilson Tang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary S. Francis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilson Tang, W., Francis, G.S. Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Curr Cardiol Rep 6, 200–204 (2004). https://doi.org/10.1007/s11886-004-0024-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-004-0024-9

Keywords

Search

Navigation